Sun Pharmaceutical Industries Ltd News

Sun Pharma's Unloxcyt posts 50% response rate in skin cancer study

Updated data from the CK-301-101 trial showed durable responses and manageable safety profile in patients with locally advanced cutaneous squamous cell carcinoma

Sun Pharma shares slip post Q4; analysts cautious on near-term upside

In the March quarter, Sun Pharma reported net profit at ₹2,714 crore, as compared to ₹2,150 crore a year ago, up 26.2 per cent year-on-year (Y-o-Y)

Sun Pharma's US generics business remains under pressure in FY26

Innovative medicines business crosses $1 billion milestone as company expands specialty pipeline and bets on Organon acquisition

Sun Pharma posts Q4 profit of ₹2,714 crore on strong specialty drug demand

India's largest drugmaker reported stronger-than-expected quarterly profit as growth in specialty medicines offset weakness in US sales

Q4 results: Sun Pharma, Eicher Motors, and Colgate among 187 on May 22

Q4FY26 company results: Firms including Hindalco Industries, Fortis Healthcare, Torrent Pharmaceuticals, Info Edge (India), and TTK Prestige are also to release their January-March earnings today

Why pharma stocks are emerging as safe bet amid global market turmoil

The pharma sector is seen as a safe bet because demand remains steady even during inflation or economic slowdowns. Besides, companies earn revenue from multiple global markets, which helps reduce risk

Organon deal impact: Sun Pharma surges 16% in 10 days, nears record high

Sun Pharma's acquisition of Organon as a transformational deal, doubling revenue to USD 12 billion with 30 per cent EBITDA margin, analysts.

Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

Analyst suggests 'Bull Spread' on Midcap Nifty, Sun Pharma; check strategy

Nandish Shah of HDFC Securities has shared Bull Spread' on strategy on Midcap Nifty and Sun Pharma

Sun Pharma exploring Eurobonds, bond swaps to fund US-based Organon buy

According to bankers, the Indian pharma major plans to raise around $10 billion from various sources, while the remaining will be funded through internal accruals

Sun Pharma up 12% in 4 days, nears 52-week high; analysts see more upside?

Supported by the Sun Pharma's proven record of strong cash flows, analysts remain confident in gradual deleveraging over time.

Sun Pharma bets on Organon front-end to drive global growth, efficiencies

Sun Pharma sees its Organon acquisition as a platform to expand globally, boost in-licensing, and improve long-term efficiencies through a stronger commercial front-end

Nifty Apr F&O rollovers hint at cautious stance; ONGC among stocks in focus

The Nifty rollovers to May were below average, suggesting a likely cautious stance among participants and slight hesitation to carry forward aggressive bets, says Axis Securities.

Sun Pharmaceutical acquires US-based Organon in $11.75 billion deal

Combined entity to have revenue of $12.4 billion; enters biosimilars big league

Lack of growth visibility at Organon could cap Sun Pharma's gains

Sun Pharma's Organon deal lifts stock, but growth concerns and high debt at the acquired firm may cap upside despite synergy potential

Sun Pharma, Dr Reddy's Labs, Onesource: Nifty Pharma rallies 3%; details

Among others, Sun Pharma was the top gainer up over 7 per cent, followed by Gland Pharma, Alkem Laboratories, Zydus Lifesciences and Wockhardt up over 2 per cent

Sun Pharma rallies 6%, top gainer among Sensex stocks; here's why

Sun Pharma to acquire all outstanding shares of Organon for $14.00 per share in an all cash transaction with an enterprise valuation of $11.75 billion.

Sun Pharma to acquire US drugmaker Organon in $11.75 billion all-cash deal

April 26 (Reuters) - India's Sun Pharmaceutical Industries ​will uy Organon & ​Co in an all-cash ‌deal, valuing the U.S. drugmaker at about $11.75 billion including ebt, the companies said on Sunday.

Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%

Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.

Pharma cos brace for soft Q4; US drag persists; domestic growth cushions

Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements